Drug Susceptibility Test Results for M. tuberculosis Complex Isolates from the CDC Model Performance Evaluation Program

Form Approved

OMB No. 0920-0600

Expiration Date: XX/XX/20XX

Instructions

- For each survey submitted, two growth-based drug susceptibility test methods and three molecular test method can be entered.

- Sensititre, if performed, must be entered as the first method.

- All results for the MPEP survey must be entered at one time.

- For questions or comments, contact TBMPEP@cdc.gov.

---

*Enter MPEP number _____
*Name of person completing form _____
*Title _____
*Email _____
*must provide value

Enter MPEP number

_____

Please indicate the primary classification of your laboratory

◯ Hospital
◯ Public Health (e.g., local, county, state, territorial)
◯ Independent/Reference (non-hospital based)
◯ Federal
◯ Other

Please describe your laboratory classification

_____

On what date were the MPEP cultures received in your laboratory?

_____

Upon arrival, what was the condition of the cultures in the panel?

◯ Satisfactory
◯ Unsatisfactory

Please describe the unsatisfactory condition of the cultures when they arrived

_____

In the last calendar year (January 1 - December 31, 2024), how many isolates of M. tuberculosis complex (MTBC) did your laboratory test for drug susceptibilities? (Please exclude quality control isolates)

_____

Did your laboratory perform MTBC growth-based drug susceptibility testing (DST) for the panel in this shipment?

◯ Yes
◯ No

What method was performed in your laboratory for MTBC growth-based drug susceptibility testing (DST) for testing the panel in this shipment?
(Only one method can be selected. If multiple methods were performed, there will be an opportunity to enter those results after the first method.)

◯ Agar Proportion (Middlebrook 7H10 or 7H11)
◯ MGIT System
◯ MIC Testing
◯ VersaTrek Myco

Isolate 2025A

Please enter your growth-based DST results

	Susceptible	Resistant	Intermediate	Contaminated / No Growth	No Interpretation	Not Done
Rifampin	◯	◯	◯	◯	◯	◯
Isoniazid low	◯	◯	◯	◯	◯	◯
Isoniazid high	◯	◯	◯	◯	◯	◯
Ethambutol	◯	◯	◯	◯	◯	◯
Pyrazinamide	◯	◯	◯	◯	◯	◯
Streptomycin	◯	◯	◯	◯	◯	◯

Did your laboratory perform growth-based DST on additional drugs by the initial method selected?

◯ Yes
◯ No

	Susceptible	Resistant	Intermediate	Contaminated / No Growth	No Interpretation	Not Done
Ofloxacin	◯	◯	◯	◯	◯	◯
Ciprofloxacin	◯	◯	◯	◯	◯	◯
Moxifloxacin	◯	◯	◯	◯	◯	◯
Levofloxacin	◯	◯	◯	◯	◯	◯
Amikacin	◯	◯	◯	◯	◯	◯
Kanamycin	◯	◯	◯	◯	◯	◯
Capreomycin	◯	◯	◯	◯	◯	◯
Rifabutin	◯	◯	◯	◯	◯	◯
Ethionamide	◯	◯	◯	◯	◯	◯
Cycloserine	◯	◯	◯	◯	◯	◯
Para-aminosalicylic Acid	◯	◯	◯	◯	◯	◯
Rifapentine	◯	◯	◯	◯	◯	◯
Bedaquiline	◯	◯	◯	◯	◯	◯
Linezolid	◯	◯	◯	◯	◯	◯
Clofazimine	◯	◯	◯	◯	◯	◯
Delamanid	◯	◯	◯	◯	◯	◯
Pretomanid	◯	◯	◯	◯	◯	◯

Comments

Isolate 2025B

Please enter growth-based drug susceptibility results

	Susceptible	Resistant	Intermediate	Contaminated / No Growth	No Interpretation	Not Done
Rifampin	◯	◯	◯	◯	◯	◯
Isoniazid low	◯	◯	◯	◯	◯	◯
Isoniazid high	◯	◯	◯	◯	◯	◯
Ethambutol	◯	◯	◯	◯	◯	◯
Pyrazinamide	◯	◯	◯	◯	◯	◯
Streptomycin	◯	◯	◯	◯	◯	◯

Did your laboratory perform growth-based DST on additional drugs by the initial method selected?

◯ Yes
◯ No

	Susceptible	Resistant	Intermediate	Contaminated / No Growth	No Interpretation	Not Done
Ofloxacin	◯	◯	◯	◯	◯	◯
Ciprofloxacin	◯	◯	◯	◯	◯	◯
Moxifloxacin	◯	◯	◯	◯	◯	◯
Levofloxacin	◯	◯	◯	◯	◯	◯
Amikacin	◯	◯	◯	◯	◯	◯
Kanamycin	◯	◯	◯	◯	◯	◯
Capreomycin	◯	◯	◯	◯	◯	◯
Ethionamide	◯	◯	◯	◯	◯	◯
Rifabutin	◯	◯	◯	◯	◯	◯
Cycloserine	◯	◯	◯	◯	◯	◯
Para-aminosalicylic Acid	◯	◯	◯	◯	◯	◯
Rifapentine	◯	◯	◯	◯	◯	◯
Bedaquiline	◯	◯	◯	◯	◯	◯
Linezolid	◯	◯	◯	◯	◯	◯
Clofazimine	◯	◯	◯	◯	◯	◯
Delamanid	◯	◯	◯	◯	◯	◯
Pretomanid	◯	◯	◯	◯	◯	◯

Comments

Isolate 2025C

Please enter growth-based drug susceptibility results

	Susceptible	Resistant	Intermediate	Contaminated / No Growth	No Interpretation	Not Done
Rifampin	◯	◯	◯	◯	◯	◯
Isoniazid low	◯	◯	◯	◯	◯	◯
Isoniazid high	◯	◯	◯	◯	◯	◯
Ethambutol	◯	◯	◯	◯	◯	◯
Pyrazinamide	◯	◯	◯	◯	◯	◯
Streptomycin	◯	◯	◯	◯	◯	◯

Did your laboratory perform growth-based DST on additional drugs by the initial method selected?

◯ Yes
◯ No

	Susceptible	Resistant	Intermediate	Contaminated / No Growth	No Interpretation	Not Done
Ofloxacin	◯	◯	◯	◯	◯	◯
Ciprofloxacin	◯	◯	◯	◯	◯	◯
Moxifloxacin	◯	◯	◯	◯	◯	◯
Levofloxacin	◯	◯	◯	◯	◯	◯
Amikacin	◯	◯	◯	◯	◯	◯
Kanamycin	◯	◯	◯	◯	◯	◯
Capreomycin	◯	◯	◯	◯	◯	◯
Ethionamide	◯	◯	◯	◯	◯	◯
Rifabutin	◯	◯	◯	◯	◯	◯
Cycloserine	◯	◯	◯	◯	◯	◯
Para-aminosalicylic Acid	◯	◯	◯	◯	◯	◯
Rifapentine	◯	◯	◯	◯	◯	◯
Bedaquiline	◯	◯	◯	◯	◯	◯
Linezolid	◯	◯	◯	◯	◯	◯
Clofazimine	◯	◯	◯	◯	◯	◯
Delamanid	◯	◯	◯	◯	◯	◯
Pretomanid	◯	◯	◯	◯	◯	◯

Comments

Isolate 2025D

Please enter growth-based drug susceptibility results

	Susceptible	Resistant	Intermediate	Contaminated / No Growth	No Interpretation	Not Done
Rifampin	◯	◯	◯	◯	◯	◯
Isoniazid low	◯	◯	◯	◯	◯	◯
Isoniazid high	◯	◯	◯	◯	◯	◯
Ethambutol	◯	◯	◯	◯	◯	◯
Pyrazinamide	◯	◯	◯	◯	◯	◯
Streptomycin	◯	◯	◯	◯	◯	◯

Did your laboratory perform growth-based DST on additional drugs by the initial method selected?

◯ Yes
◯ No

	Susceptible	Resistant	Intermediate	Contaminated / No Growth	No Interpretation	Not Done
Ofloxacin	◯	◯	◯	◯	◯	◯
Ciprofloxacin	◯	◯	◯	◯	◯	◯
Moxifloxacin	◯	◯	◯	◯	◯	◯
Levofloxacin	◯	◯	◯	◯	◯	◯
Amikacin	◯	◯	◯	◯	◯	◯
Kanamycin	◯	◯	◯	◯	◯	◯
Capreomycin	◯	◯	◯	◯	◯	◯
Ethionamide	◯	◯	◯	◯	◯	◯
Rifabutin	◯	◯	◯	◯	◯	◯
Cycloserine	◯	◯	◯	◯	◯	◯
Para-aminosalicylic Acid	◯	◯	◯	◯	◯	◯
Rifapentine	◯	◯	◯	◯	◯	◯
Bedaquiline	◯	◯	◯	◯	◯	◯
Linezolid	◯	◯	◯	◯	◯	◯
Clofazamine	◯	◯	◯	◯	◯	◯
Delamanid	◯	◯	◯	◯	◯	◯
Pretomanid	◯	◯	◯	◯	◯	◯

Comments

Isolate 2025E

Please enter growth-based drug susceptibility results

	Susceptible	Resistant	Intermediate	Contaminated / No Growth	No Interpretation	Not Done
Rifampin	◯	◯	◯	◯	◯	◯
Isoniazid low	◯	◯	◯	◯	◯	◯
Isoniazid high	◯	◯	◯	◯	◯	◯
Ethambutol	◯	◯	◯	◯	◯	◯
Pyrazinamide	◯	◯	◯	◯	◯	◯
Streptomycin	◯	◯	◯	◯	◯	◯

Did your laboratory perform growth-based DST on additional drugs by the initial method selected?

◯ Yes
◯ No

	Susceptible	Resistant	Intermediate	Contaminated / No Growth	No Interpretation	Not Done
Ofloxacin	◯	◯	◯	◯	◯	◯
Ciprofloxacin	◯	◯	◯	◯	◯	◯
Moxifloxacin	◯	◯	◯	◯	◯	◯
Levofloxacin	◯	◯	◯	◯	◯	◯
Amikacin	◯	◯	◯	◯	◯	◯
Kanamycin	◯	◯	◯	◯	◯	◯
Capreomycin	◯	◯	◯	◯	◯	◯
Ethionamide	◯	◯	◯	◯	◯	◯
Rifabutin	◯	◯	◯	◯	◯	◯
Cycloserine	◯	◯	◯	◯	◯	◯
Para-aminosalicylic Acid	◯	◯	◯	◯	◯	◯
Rifapentine	◯	◯	◯	◯	◯	◯
Bedaquiline	◯	◯	◯	◯	◯	◯
Linezolid	◯	◯	◯	◯	◯	◯
Clofazimine	◯	◯	◯	◯	◯	◯
Delamanid	◯	◯	◯	◯	◯	◯
Pretomanid	◯	◯	◯	◯	◯	◯

Comments

_____

Please provide the specific MIC testing method performed

_____

Isolate 2025A MIC Testing Results

Enter MIC drug susceptibility interpretation Enter quantitative MIC results (ug/ml)
Rifampin _____ _____
Isoniazid low _____ _____
Isoniazid high _____ _____
Ethambutol _____

_____

Streptomycin

_____

Ofloxacin

_____

_____

Ciprofloxacin

_____

_____

Moxifloxacin

_____

_____

Levofloxacin

_____

_____

Amikacin

_____

_____

Kanamycin

_____

_____

Capreomycin

_____

_____

Ethionamide

_____

_____

Rifabutin

_____

_____

Cycloserine

_____

_____

Para-aminosalicylic Acid

_____

_____

Rifapentine

_____

_____

Bedaquiline

_____

_____

Linezolid

_____

_____

Clofazimine

_____

_____

Delamanid

_____

_____

Pretomanid

_____

_____

Additional MIC Comments

_____

Isolate 2025B MIC Testing Results

Enter MIC drug susceptibility interpretation Enter quantitative MIC results (ug/ml)

Rifampin _____ _____
Isoniazid low _____ _____
Isoniazid high _____ _____
Ethambutol _____ _____
Streptomycin _____ _____
Ofloxacin _____ _____
Ciprofloxacin _____ _____
Moxifloxacin _____ _____
Levofloxacin _____ _____
Amikacin _____ _____
Kanamycin _____ _____
Capreomycin _____ _____
Ethionamide _____ _____
Rifabutin _____ _____
Cycloserine _____ _____
Para-aminosalicylic Acid _____ _____
Rifapentine _____ _____
Bedaquiline _____ _____
Linezolid _____ _____
Clofazimine _____ _____
Delamanid _____ _____
Pretomanid _____ _____

Additional MIC Comments

_____

Isolate 2025C MIC Testing Results

Enter MIC drug susceptibility interpretation Enter quantitative MIC results (ug/ml)

Rifampin _____ _____
Isoniazid low _____ _____
Isoniazid high _____ _____
Ethambutol _____ _____
Streptomycin _____ _____
Ofloxacin _____ _____
Ciprofloxacin _____ _____
Moxifloxacin _____ _____
Levofloxacin _____ _____
Amikacin _____ _____
Kanamycin _____ _____
Capreomycin _____ _____
Ethionamide _____ _____
Rifabutin _____ _____
Cycloserine _____ _____
Para-aminosalicylic Acid _____ _____
Rifapentine _____ _____
Bedaquiline _____ _____
Linezolid _____ _____
Clofazimine _____ _____
Delamanid _____ _____
Pretomanid _____ _____

Additional MIC Comments

_____

Isolate 2025D MIC Testing Results

Enter MIC drug susceptibility interpretation Enter quantitative MIC results (ug/ml)

Rifampin _____ _____
Isoniazid low _____ _____
Isoniazid high _____ _____
Ethambutol _____ _____
Streptomycin _____ _____
Ofloxacin _____ _____
Ciprofloxacin _____ _____
Moxifloxacin _____ _____
Levofloxacin _____ _____
Amikacin _____ _____
Kanamycin _____ _____
Capreomycin _____ _____
Ethionamide _____ _____
Rifabutin _____ _____
Cycloserine _____ _____
Para-aminosalicylic Acid _____ _____
Rifapentine _____ _____
Bedaquiline _____ _____
Linezolid _____ _____
Clofazimine _____ _____
Delamanid _____ _____
Pretomanid _____ _____

Additional MIC Comments

_____

Isolate 2025E MIC Testing Results

Enter MIC drug susceptibility interpretation Enter quantitative MIC results (ug/ml)

Rifampin _____ _____
Isoniazid low _____ _____
Isoniazid high _____ _____
Ethambutol _____ _____
Streptomycin _____ _____
Ofloxacin _____ _____
Ciprofloxacin _____ _____
Moxifloxacin _____ _____
Levofloxacin _____ _____
Amikacin _____ _____
Kanamycin _____ _____
Capreomycin _____ _____
Ethionamide _____ _____
Rifabutin _____ _____
Cycloserine _____ _____
Para-aminosalicylic Acid _____ _____
Rifapentine _____ _____
Bedaquiline _____ _____
Linezolid _____ _____
Clofazimine _____ _____
Delamanid _____ _____
Pretomanid _____ _____

Additional MIC Comments

_____

Did your laboratory perform a second growth-based DST method?	◯ Yes ◯ No
Select the second growth-based DST method:	◯ Agar Proportion ◯ MGIT System ◯ VersaTrek Myco

Isolate 2025A--Test Method 2

For your second growth-based method, enter drug susceptibility results.

	Susceptible	Resistant	Intermediate	Contaminated / No Growth	No Interpretation	Not Done
Rifampin	◯	◯	◯	◯	◯	◯
Isoniazid low	◯	◯	◯	◯	◯	◯
Isoniazid high	◯	◯	◯	◯	◯	◯
Ethambutol	◯	◯	◯	◯	◯	◯
Pyrazinamide	◯	◯	◯	◯	◯	◯
Streptomycin	◯	◯	◯	◯	◯	◯

For this second test method, did your laboratory perform DST on additional drugs?

◯ Yes
◯ No

	Susceptible	Resistant	Intermediate	Contaminated / No Growth	No Interpretation	Not Done
Ofloxacin	◯	◯	◯	◯	◯	◯
Ciprofloxacin	◯	◯	◯	◯	◯	◯
Moxifloxacin	◯	◯	◯	◯	◯	◯
Levofloxacin	◯	◯	◯	◯	◯	◯
Amikacin	◯	◯	◯	◯	◯	◯
Kanamycin	◯	◯	◯	◯	◯	◯
Capreomycin	◯	◯	◯	◯	◯	◯
Ethionamide	◯	◯	◯	◯	◯	◯
Rifabutin	◯	◯	◯	◯	◯	◯
Cycloserine	◯	◯	◯	◯	◯	◯
Para-aminosalicylic Acid	◯	◯	◯	◯	◯	◯
Rifapentine	◯	◯	◯	◯	◯	◯
Bedaquiline	◯	◯	◯	◯	◯	◯
Linezolid	◯	◯	◯	◯	◯	◯
Clofazimine	◯	◯	◯	◯	◯	◯
Delamanid	◯	◯	◯	◯	◯	◯
Pretomanid	◯	◯	◯	◯	◯	◯

Comments

Isolate 2025B--Test Method 2

For your second growth-based method, enter drug susceptibility results.

	Susceptible	Resistant	Intermediate	Contaminated / No Growth	No Interpretation	Not Done
Rifampin	◯	◯	◯	◯	◯	◯
Isoniazid low	◯	◯	◯	◯	◯	◯
Isoniazid high	◯	◯	◯	◯	◯	◯
Ethambutol	◯	◯	◯	◯	◯	◯
Pyrazinamide	◯	◯	◯	◯	◯	◯
Streptomycin	◯	◯	◯	◯	◯	◯

For this second test method, did your laboratory perform DST on additional drugs?

◯ Yes
◯ No

	Susceptible	Resistant	Intermediate	Contaminated / No Growth	No Interpretation	Not Done
Ofloxacin	◯	◯	◯	◯	◯	◯
Ciprofloxacin	◯	◯	◯	◯	◯	◯
Moxifloxacin	◯	◯	◯	◯	◯	◯
Levofloxacin	◯	◯	◯	◯	◯	◯
Amikacin	◯	◯	◯	◯	◯	◯
Kanamycin	◯	◯	◯	◯	◯	◯
Capreomycin	◯	◯	◯	◯	◯	◯
Ethionamide	◯	◯	◯	◯	◯	◯
Rifabutin	◯	◯	◯	◯	◯	◯
Cycloserine	◯	◯	◯	◯	◯	◯
Para-aminosalicylic Acid	◯	◯	◯	◯	◯	◯
Rifapentine	◯	◯	◯	◯	◯	◯
Bedaquiline	◯	◯	◯	◯	◯	◯
Linezolid	◯	◯	◯	◯	◯	◯
Clofazimine	◯	◯	◯	◯	◯	◯
Delamanid	◯	◯	◯	◯	◯	◯
Pretomanid	◯	◯	◯	◯	◯	◯

Comments

Isolate 2025C--Test Method 2

For your second growth-based method, enter drug susceptibility results.

	Susceptible	Resistant	Intermediate	Contaminated / No Growth	No Interpretation	Not Done
Rifampin	◯	◯	◯	◯	◯	◯
Isoniazid low	◯	◯	◯	◯	◯	◯
Isoniazid high	◯	◯	◯	◯	◯	◯
Ethambutol	◯	◯	◯	◯	◯	◯
Pyrazinamide	◯	◯	◯	◯	◯	◯
Streptomycin	◯	◯	◯	◯	◯	◯

For this second test method, did your laboratory perform DST on additional drugs?

◯ Yes
◯ No

	Susceptible	Resistant	Intermediate	Contaminated / No Growth	No Interpretation	Not Done
Ofloxacin	◯	◯	◯	◯	◯	◯
Ciprofloxacin	◯	◯	◯	◯	◯	◯
Moxifloxacin	◯	◯	◯	◯	◯	◯
Levofloxacin	◯	◯	◯	◯	◯	◯
Amikacin	◯	◯	◯	◯	◯	◯
Kanamycin	◯	◯	◯	◯	◯	◯
Capreomycin	◯	◯	◯	◯	◯	◯
Ethionamide	◯	◯	◯	◯	◯	◯
Rifabutin	◯	◯	◯	◯	◯	◯
Cycloserine	◯	◯	◯	◯	◯	◯
Para-aminosalicylic Acid	◯	◯	◯	◯	◯	◯
Rifapentine	◯	◯	◯	◯	◯	◯
Bedaquiline	◯	◯	◯	◯	◯	◯
Linezolid	◯	◯	◯	◯	◯	◯
Clofazimine	◯	◯	◯	◯	◯	◯
Delamanid	◯	◯	◯	◯	◯	◯
Pretomanid	◯	◯	◯	◯	◯	◯

Comments

Isolate 2025D--Test Method 2

For your second growth-based method, enter drug susceptibility results.

	Susceptible	Resistant	Intermediate	Contaminated / No Growth	No Interpretation	Not Done
Rifampin	◯	◯	◯	◯	◯	◯
Isoniazid low	◯	◯	◯	◯	◯	◯
Isoniazid high	◯	◯	◯	◯	◯	◯
Ethambutol	◯	◯	◯	◯	◯	◯
Pyrazinamide	◯	◯	◯	◯	◯	◯
Streptomycin	◯	◯	◯	◯	◯	◯

For this second test method, did your laboratory perform DST on additional drugs?

◯ Yes
◯ No

	Susceptible	Resistant	Intermediate	Contaminated / No Growth	No Interpretation	Not Done
Ofloxacin	◯	◯	◯	◯	◯	◯
Ciprofloxacin	◯	◯	◯	◯	◯	◯
Moxifloxacin	◯	◯	◯	◯	◯	◯
Levofloxacin	◯	◯	◯	◯	◯	◯
Amikacin	◯	◯	◯	◯	◯	◯
Kanamycin	◯	◯	◯	◯	◯	◯
Capreomycin	◯	◯	◯	◯	◯	◯
Ethionamide	◯	◯	◯	◯	◯	◯
Rifabutin	◯	◯	◯	◯	◯	◯
Cycloserine	◯	◯	◯	◯	◯	◯
Para-Aminosalicylic Acid	◯	◯	◯	◯	◯	◯
Rifapentine	◯	◯	◯	◯	◯	◯
Clofazamine	◯	◯	◯	◯	◯	◯
Delamanid	◯	◯	◯	◯	◯	◯
Pretomanid	◯	◯	◯	◯	◯	◯

Comments

Isolate 2025E--Test Method 2

For your second growth-based method, enter drug susceptibility results.

	Susceptible	Resistant	Intermediate	Contaminated / No Growth	No Interpretation	Not Done
Rifampin	◯	◯	◯	◯	◯	◯
Isoniazid low	◯	◯	◯	◯	◯	◯
Isoniazid high	◯	◯	◯	◯	◯	◯
Ethambutol	◯	◯	◯	◯	◯	◯
Pyrazinamide	◯	◯	◯	◯	◯	◯
Streptomycin	◯	◯	◯	◯	◯	◯

For this second test method, did your laboratory perform DST on additional drugs?
◯ Yes
◯ No

	Susceptible	Resistant	Intermediate	Contaminated / No Growth	No Interpretation	Not Done
Ofloxacin	◯	◯	◯	◯	◯	◯
Ciprofloxacin	◯	◯	◯	◯	◯	◯
Moxifloxacin	◯	◯	◯	◯	◯	◯
Levofloxacin	◯	◯	◯	◯	◯	◯
Amikacin	◯	◯	◯	◯	◯	◯
Kanamycin	◯	◯	◯	◯	◯	◯
Capreomycin	◯	◯	◯	◯	◯	◯
Ethionamide	◯	◯	◯	◯	◯	◯
Rifabutin	◯	◯	◯	◯	◯	◯
Cycloserine	◯	◯	◯	◯	◯	◯
Para-Aminosalicylic Acid	◯	◯	◯	◯	◯	◯
Rifapentine	◯	◯	◯	◯	◯	◯
Bedaquiline	◯	◯	◯	◯	◯	◯
Linezolid	◯	◯	◯	◯	◯	◯
Clofazimine	◯	◯	◯	◯	◯	◯
Delamanid	◯	◯	◯	◯	◯	◯
Pretomanid	◯	◯	◯	◯	◯	◯

Comments

_____

Did your laboratory perform detection of drug resistance using a molecular method?
◯ Yes
◯ No

Please select the molecular method performed

◯ Xpert MTB/RIF (Cepheid)
◯ Genotype MTDRplus/MTDRsl (Hain Lifescience)
◯ Conventional Targeted DNA Sequencing (e.g., pyrosequencing, Sanger)
◯ Next Generation Targeted DNA Sequencing (e.g., Illumina amplicon sequencing, Deeplex Myc-TB, Nanopore)
◯ Whole Genome Sequencing
◯ Other method

Please provide the specific Next Generation Targeted DNA sequencing method performed _____

Please provide the specific Whole Genome Sequencing method performed _____

Please provide the Other molecular method performed _____

Isolate 2025A Molecular Results Please enter your reportable molecular results.

Enter molecular results Enter specific mutation(s) detected
Rifamycins (Rifampin, Rifabutin, Rifapentine) _____ _____
Isoniazid _____ _____
Ethambutol _____ _____
Pyrazinamide _____ _____
Streptomycin _____ _____
Fluoroquinolones (Moxifloxacin, Levofloxacin, Ofloxacin)

_____ _____
Amikacin _____ _____
Kanamycin _____ _____
Capreomycin _____ _____
Ethionamide _____ _____
Cycloserine _____ _____
Para-aminosalicylic Acid _____ _____
Bedaquiline _____ _____
Linezolid _____ _____
Clofazimine _____ _____
Delamanid _____ _____
Pretomanid _____ _____

Additional Molecular Comments _____

Isolate 2025B Molecular Results Please enter your reportable molecular results.

Enter molecular results Enter specific mutation(s) detected
Rifamycins (Rifampin, Rifabutin, Rifapentine) _____ _____
Isoniazid _____ _____
Ethambutol _____ _____
Pyrazinamide _____ _____
Streptomycin _____ _____
Fluoroquinolones (Moxifloxacin, Levofloxacin, Ofloxacin)

_____ _____
Amikacin _____ _____
Kanamycin _____ _____
Capreomycin _____ _____
Ethionamide _____ _____
Cycloserine _____ _____
Para-aminosalicylic Acid _____ _____
Bedaquiline _____ _____
Linezolid _____ _____
Clofazimine _____ _____

Delamanid _____ _____
Pretomanid _____ _____

Additional Molecular Comments

_____

Isolate 2025C Molecular Results Please enter your reportable molecular results.

Enter molecular results Enter specific mutation(s) detected
Rifamycins (Rifampin, Rifabutin, Rifapentine) _____ _____
Isoniazid _____ _____
Ethambutol _____ _____
Pyrazinamide _____ _____
Streptomycin _____ _____
Fluoroquinolones (Moxifloxacin, Levofloxacin, Ofloxacin)

_____ _____
Amikacin _____ _____
Kanamycin _____ _____
Capreomycin _____ _____
Ethionamide _____ _____
Cycloserine _____ _____
Para-aminosalicylic Acid _____ _____
Bedaquiline _____ _____
Linezolid _____ _____
Clofazimine _____ _____
Delamanid _____ _____
Pretomanid _____ _____

Additional Molecular Comments

_____

Isolate 2025D Molecular Results Please enter your reportable molecular results.

Enter molecular results Enter specific mutation(s) detected
Rifamycins (Rifampin, Rifabutin, Rifapentine) _____ _____
Isoniazid _____ _____
Ethambutol _____ _____
Pyrazinamide _____ _____
Streptomycin _____ _____
Fluoroquinolones (Moxifloxacin, Levofloxacin, Ofloxacin)

_____ _____
Amikacin _____ _____
Kanamycin _____ _____
Capreomycin _____ _____
Ethionamide _____ _____
Cycloserine _____ _____
Para-aminosalicylic Acid _____ _____
Bedaquiline _____ _____
Linezolid _____ _____
Clofazimine _____ _____
Delamanid _____ _____
Pretomanid _____ _____

Additional Molecular Comments

_____

Isolate 2025E Molecular Results Please enter your reportable molecular results.

	Enter molecular results	Enter specific mutation(s) detected
Rifamycins (Rifampin, Rifabutin, Rifapentine)	_____	_____
Isoniazid	_____	_____
Ethambutol	_____	_____
Pyrazinamide	_____	_____
Streptomycin	_____	_____
Fluoroquinolones (Moxifloxacin, Levofloxacin, Ofloxacin)	_____	_____
Amikacin	_____	_____
Kanamycin	_____	_____
Capreomycin	_____	_____
Ethionamide	_____	_____
Cycloserine	_____	_____
Para-aminosalicylic Acid	_____	_____
Bedaquiline	_____	_____
Linezolid	_____	_____
Clofazimine	_____	_____
Delamanid	_____	_____
Pretomanid	_____	_____

Additional Molecular Comments

_____

Did your laboratory perform a second molecular method for detection of drug resistance?

- ◯ Yes
- ◯ No

Please select the molecular method performed

- ◯ Xpert MTB/RIF (Cepheid)
- ◯ Genotype MTDRplus/MTDRsl (Hain Lifescience)
- ◯ Conventional Targeted DNA Sequencing (e.g., pyrosequencing, Sanger)
- ◯ Next Generation Targeted DNA Sequencing (e.g., Illumina amplicon sequencing, Deeplex Myc-TB, Nanopore)
- ◯ Whole Genome Sequencing
- ◯ Other method

Please provide the specific Next Generation Targeted DNA sequencing method performed

_____

Please provide the specific Whole Genome Sequencing method performed

_____

Please provide the Other molecular method performed

_____

Isolate 2025A Molecular Results--Test Method 2 Please enter your reportable molecular DST results.

	Enter molecular results	Enter specific mutation(s) detected
Rifamycins (Rifampin, Rifabutin, Rifapentine)	_____	_____
Isoniazid	_____	_____
Ethambutol	_____	_____
Pyrazinamide	_____	_____
Streptomycin	_____	_____
Fluoroquinolones (Moxifloxacin, Levofloxacin, Ofloxacin)	_____	_____
Amikacin	_____	_____
Kanamycin	_____	_____
Capreomycin	_____	_____
Ethionamide	_____	_____
Cycloserine	_____	_____
Para-aminosalicylic Acid	_____	_____
Bedaquiline	_____	_____
Linezolid	_____	_____

Clofazimine _____ _____
Delamanid _____ _____
Pretomanid _____ _____

Additional Molecular Comments

_____

Isolate 2025B Molecular Results--Test Method 2 Please enter your reportable molecular DST results.

Enter molecular results Enter specific mutation(s) detected
Rifamycins (Rifampin, Rifabutin, Rifapentine) _____ _____
Isoniazid _____ _____
Ethambutol _____ _____
Pyrazinamide _____ _____
Streptomycin _____ _____
Fluoroquinolones (Moxifloxacin, Levofloxacin, Ofloxacin)

_____ _____
Amikacin _____ _____
Kanamycin _____ _____
Capreomycin _____ _____
Ethionamide _____ _____
Cycloserine _____ _____
Para-aminosalicylic Acid _____ _____
Bedaquiline _____ _____
Linezolid _____ _____
Clofazimine _____ _____
Delamanid _____ _____
Pretomanid _____ _____

Additional Molecular Comments

_____

Isolate 2025C Molecular Results--Test Method 2 Please enter your reportable molecular DST results.

Enter molecular results Enter specific mutation(s) detected
Rifamycins (Rifampin, Rifabutin, Rifapentine) _____ _____
Isoniazid _____ _____
Ethambutol _____ _____
Pyrazinamide _____ _____
Streptomycin _____ _____
Fluoroquinolones (Moxifloxacin, Levofloxacin, Ofloxacin)

_____ _____
Amikacin _____ _____
Kanamycin _____ _____
Capreomycin _____ _____
Ethionamide _____ _____
Cycloserine _____ _____
Para-aminosalicylic Acid _____ _____
Bedaquiline _____ _____
Linezolid _____ _____
Clofazimine _____ _____
Delamanid _____ _____
Pretomanid _____ _____

Additional Molecular Comments

_____

Isolate 2025D Molecular Results--Test Method 2 Please enter your reportable molecular DST results.

Enter molecular results Enter specific mutation(s) detected
Rifamycins (Rifampin, Rifabutin, Rifapentine) _____ _____
Isoniazid _____ _____
Ethambutol _____ _____
Pyrazinamide _____ _____
Streptomycin _____ _____
Fluoroquinolones (Moxifloxacin, Levofloxacin, Ofloxacin)

_____ _____
Amikacin _____ _____
Kanamycin _____ _____
Capreomycin _____ _____
Ethionamide _____ _____
Cycloserine _____ _____
Para-aminosalicylic Acid _____ _____
Bedaquiline _____ _____
Linezolid _____ _____
Clofazimine _____ _____
Delamanid _____ _____
Pretomanid _____ _____

Additional Molecular Comments

_____

Isolate 2025E Molecular Results--Test Method 2 Please enter your reportable molecular DST results.

Enter molecular results Enter specific mutation(s) detected
Rifamycins (Rifampin, Rifabutin, Rifapentine) _____ _____
Isoniazid _____ _____
Ethambutol _____ _____
Pyrazinamide _____ _____
Streptomycin _____ _____
Fluoroquinolones (Moxifloxacin, Levofloxacin, Ofloxacin) _____ _____
Amikacin _____ _____
Kanamycin _____ _____
Capreomycin _____ _____
Ethionamide _____ _____
Cycloserine _____ _____
Para-aminosalicylic Acid _____ _____
Bedaquiline _____ _____
Linezolid _____ _____
Clofazimine _____ _____
Delamanid _____ _____
Pretomanid _____ _____

Additional Molecular Comments

_____

Did your laboratory perform a third molecular method for detection of drug resistance?
◯ Yes
◯ No

Please select the molecular method performed

- ◯ Xpert MTB/RIF (Cepheid)
- ◯ Genotype MTDRplus/MTDRsl (Hain Lifescience)
- ◯ Conventional Targeted DNA Sequencing (e.g., pyrosequencing, Sanger)
- ◯ Next Generation Targeted DNA Sequencing (e.g., Illumina amplicon sequencing, Deeplex Myc-TB, Nanopore)
- ◯ Whole Genome Sequencing
- ◯ Other method

Please provide the specific Next Generation Targeted DNA sequencing method performed

_____

Please provide the specific Whole Genome Sequencing method performed

_____

Please provide the Other molecular method performed

_____

Isolate 2025A Molecular Results--Test Method 3 Please enter your reportable molecular DST results.

	Enter molecular results	Enter specific mutation(s) detected
Rifamycins (Rifampin, Rifabutin, Rifapentine)	_____	_____
Isoniazid	_____	_____
Ethambutol	_____	_____
Pyrazinamide	_____	_____
Streptomycin	_____	_____
Fluoroquinolones (Moxifloxacin, Levofloxacin, Ofloxacin)	_____	_____
Amikacin	_____	_____
Kanamycin	_____	_____
Capreomycin	_____	_____
Ethionamide	_____	_____
Cycloserine	_____	_____
Para-aminosalicylic Acid	_____	_____
Bedaquiline	_____	_____
Linezolid	_____	_____
Clofazimine	_____	_____
Delamanid	_____	_____
Pretomanid	_____	_____

Additional Molecular Comments

_____

Isolate 2025B Molecular Results--Test Method 3 Please enter your reportable molecular DST results.

	Enter molecular results	Enter specific mutation(s) detected
Rifamycins (Rifampin, Rifabutin, Rifapentine)	_____	_____
Isoniazid	_____	_____
Ethambutol	_____	_____
Pyrazinamide	_____	_____
Streptomycin	_____	_____
Fluoroquinolones (Moxifloxacin, Levofloxacin, Ofloxacin)	_____	_____
Amikacin	_____	_____
Kanamycin	_____	_____
Capreomycin	_____	_____
Ethionamide	_____	_____
Cycloserine	_____	_____
Para-aminosalicylic Acid	_____	_____
Bedaquiline	_____	_____
Linezolid	_____	_____
Clofazimine	_____	_____
Delamanid	_____	_____
Pretomanid	_____	_____

Additional Molecular Comments

_____

Isolate 2025C Molecular Results--Test Method 3 Please enter your reportable molecular DST results.

Enter molecular results Enter specific mutation(s) detected
Rifamycins (Rifampin, Rifabutin, Rifapentine) _____ _____
Isoniazid _____ _____
Ethambutol _____ _____
Pyrazinamide _____ _____
Streptomycin _____ _____
Fluoroquinolones (Moxifloxacin, Levofloxacin, Ofloxacin) _____ _____
Amikacin _____ _____
Kanamycin _____ _____
Capreomycin _____ _____
Ethionamide _____ _____
Cycloserine _____ _____
Para-aminosalicylic Acid _____ _____
Bedaquiline _____ _____
Linezolid _____ _____
Clofazimine _____ _____
Delamanid _____ _____
Pretomanid _____ _____

Additional Molecular Comments

_____

Isolate 2025D Molecular Results--Test Method 3 Please enter your reportable molecular DST results.

Enter molecular results Enter specific mutation(s) detected
Rifamycins (Rifampin, Rifabutin, Rifapentine) _____ _____
Isoniazid _____ _____
Ethambutol _____ _____
Pyrazinamide _____ _____
Streptomycin _____ _____
Fluoroquinolones (Moxifloxacin, Levofloxacin, Ofloxacin) _____ _____
Amikacin _____ _____
Kanamycin _____ _____
Capreomycin _____ _____
Ethionamide _____ _____
Cycloserine _____ _____
Para-aminosalicylic Acid _____ _____
Bedaquiline _____ _____
Linezolid _____ _____
Clofazimine _____ _____
Delamanid _____ _____
Pretomanid _____ _____

Additional Molecular Comments

_____

Isolate 2025E Molecular Results--Test Method 3 Please enter your reportable molecular DST results.

Enter molecular results Enter specific mutation(s) detected
Rifamycins (Rifampin, Rifabutin, Rifapentine) _____ _____
Isoniazid _____ _____
Ethambutol _____ _____
Pyrazinamide _____ _____
Streptomycin _____ _____
Fluoroquinolones (Moxifloxacin, Levofloxacin, Ofloxacin) _____ _____
Amikacin _____ _____
Kanamycin _____ _____
Capreomycin _____ _____

Ethionamide _____ _____
Cycloserine _____ _____
Para-aminosalicylic Acid _____ _____
Bedaquiline _____ _____
Linezolid _____ _____
Clofazimine _____ _____
Delamanid _____ _____
Pretomanid _____ _____

Additional Molecular Comments

_____

Thank you for completing the survey.
Upon submission, you will have the opportunity to save a copy of your submitted responses.

Please either download a PDF copy or send a PDF copy by email on the next screen.